GILEAD SCIENCES, INC. (GILD)

Biological Products, (No Diagnostic Substances)

Latest Price

$146.41

TTM P/E

Normalized P/E

67.72

Div Yield

2.20%

Book Value

9.52

P/B Ratio

15.38

Valuation metrics

EPS: $6.78

Book value / share: $18.29

Formula: √(22.5 × EPS × BVPS)

Graham Number

$52.83

64% downside

Norm. op. income: $7.3B (median of 7yr)

Tax rate: 21%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$30.18

79% downside

Base FCF: $9.5B (median of recent 5yr)

Growth: -9%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$31.86

78% downside

EPS: $6.78

Target P/E: 68×

Formula: EPS × P/E

P/E Fair Value

$461.04

+215% upside

89.5% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	121.84M	$15.39B	9.82%	+2.83M	2026-06-30
VANGUARD CAPITAL MANAGEMENT LLC	81.09M	$10.24B	6.53%	+437.0K	2026-06-30
FMR LLC	66.87M	$8.45B	5.39%	-5.04M	2026-06-30
STATE STREET CORP	61.22M	$7.73B	4.93%	+1.36M	2026-06-30
Capital World Investors	40.99M	$5.18B	3.30%	-295.0K	2026-06-30
Invesco Ltd.	39.82M	$5.03B	3.21%	+24.29M	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT LLC	35.32M	$4.46B	2.85%	+186.7K	2026-06-30
GEODE CAPITAL MANAGEMENT, LLC	30.07M	$3.79B	2.42%	+339.6K	2026-06-30
PRICE T ROWE ASSOCIATES INC /MD/	30.00M	$3.79B	2.42%	+3.75M	2026-06-30
MORGAN STANLEY	24.00M	$3.03B	1.93%	+705.1K	2026-06-30